P53 Mutation and LOH at Chromosome 9 in Urothelial Carcinoma

被引:0
作者
Beothe, Tamas [2 ,3 ]
Nagy, Anetta [2 ]
Farkas, Laszlo [3 ]
Kovacs, Gyula [1 ,2 ]
机构
[1] Univ Pecs, Sch Med, Dept Lab Med, H-7624 Pecs, Hungary
[2] Univ Heidelberg, Fac Med, Heidelberg, Germany
[3] Univ Pecs, Sch Med, Dept Urol, H-7624 Pecs, Hungary
关键词
Urothelial carcinoma; chromosome 17p LOH; p53; mutation; chromosome; 9; LOH; developmental pathway; TRANSITIONAL-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; BLADDER-CANCER; IDENTIFIES PTPRD; URINARY-BLADDER; HYPERMETHYLATION; PROGRESSION; KINASE; GLIOBLASTOMA; ASSOCIATION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Mutation of the p.5.3 gene has been implicated in the development of carcinoma in situ (CIS) to invasive solid urothelial carcinomas (UC) whereas loss of heterozygosity (LOH) at chromosome 9 has been suggested to plag part in the development of papillary UCs. Patients and Methods: The p53 mutation and LOH at chromosomes 17p13.1 and 9 were analysed in 120 UCs. Tumor and matched normal DNA were used for microsatellite allelotyping of chromosome 17p and the entire chromosome 9. Results: LOH at 17p13.1 was found in each grade and stage of the UCs, but mutation of the p53 occurred only in the highly malignant G3 tumors including papillary pT1G3 UCs. LOH were found at one or more of the seven tumor suppressor gene loci along chromosome 9 in all but two of the UCs with p53 mutation. Conclusion: Mutation of the p53 gene is not a pathway correlated genetic change, but is associated with the increased cell proliferation of G3 UCs.
引用
收藏
页码:523 / 527
页数:5
相关论文
共 29 条
[11]   A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: Localization of the candidate region within a single 840 kb YAC [J].
Habuchi, T ;
Yoshida, O ;
Knowles, MA .
HUMAN MOLECULAR GENETICS, 1997, 6 (06) :913-919
[12]  
Hartmann A, 2002, CANCER RES, V62, P809
[13]   Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma [J].
Hartmann, A ;
Moser, K ;
Kriegmair, M ;
Hofstetter, A ;
Hofstaedter, F ;
Knuechel, R .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (03) :721-727
[14]   FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas:: Independent distribution and lack of association with prognosis [J].
Hernández, S ;
López-Knowles, E ;
Lloreta, J ;
Kogevinas, M ;
Jaramillo, R ;
Amorós, A ;
Tardón, A ;
García-Closas, R ;
Serra, C ;
Carrato, A ;
Malats, N ;
Real, FX .
CLINICAL CANCER RESEARCH, 2005, 11 (15) :5444-5450
[15]   Mutation of the 9q34 gene TSC1 in sporadic bladder cancer [J].
Hornigold, N ;
Devlin, J ;
Davies, AM ;
Aveyard, JS ;
Habuchi, T ;
Knowles, MA .
ONCOGENE, 1999, 18 (16) :2657-2661
[16]   A Catalog of Genes Homozygously Deleted in Human Lung Cancer and the Candidacy of PTPRD as a Tumor Suppressor Gene [J].
Kohno, Takashi ;
Otsuka, Ayaka ;
Girard, Luc ;
Sato, Masanori ;
Iwakawa, Reika ;
Ogiwara, Hideaki ;
Sanchez-Cespedes, Montse ;
Minna, John D. ;
Yokota, Jun .
GENES CHROMOSOMES & CANCER, 2010, 49 (04) :342-352
[17]   Alteration of the LRP1B gene region is associated with high grade of urothelial cancer [J].
Langbein, S ;
Szakacs, O ;
Wilhelm, M ;
Sukosd, F ;
Weber, S ;
Jauch, A ;
Beltran, AL ;
Alken, P ;
Kälble, T ;
Kovacs, G .
LABORATORY INVESTIGATION, 2002, 82 (05) :639-643
[18]   PTCH gene mutations in invasive transitional cell carcinoma of the bladder [J].
McGarvey, TW ;
Maruta, Y ;
Tomaszewski, JE ;
Linnenbach, AJ ;
Malkowicz, SB .
ONCOGENE, 1998, 17 (09) :1167-1172
[19]   DNA methylation alterations in urothelial carcinoma [J].
Neuhausen, Anne ;
Florl, Andrea R. ;
Grimm, Marc-Oliver ;
Schulz, Wolfgang A. .
CANCER BIOLOGY & THERAPY, 2006, 5 (08) :993-1001
[20]   Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms [J].
Pymar, Louis S. ;
Platt, Fiona M. ;
Askham, Jon M. ;
Morrison, Ewan E. ;
Knowles, Margaret A. .
HUMAN MOLECULAR GENETICS, 2008, 17 (13) :2006-2017